Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy

Peter Aaby, T G Jensen, H L Hansen, H Kristiansen, J Thårup, A Poulsen, Morten Sodemann, M Jakobsen, K Knudsen, M Clotilde da Silva

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

In a randomised study of 558 children in an urban African community, the protective effect of the Edmonston-Zagreb (EZ) measles vaccine given in a dose of 40,000 plaque forming units from the age of 4 months was compared with the effects of a standard dose (6000 tissue culture infectious units) of Schwarz measles vaccine given from the age of 9 months. During two years of follow-up, all 14 clinical cases of measles occurred in the Schwarz group; 10 of the children contracted measles before vaccination and 4 after measles vaccination. Thus the EZ vaccine provided significant protection against measles both before and after the usual age of vaccination. Among the children who were exposed to measles at home, those given EZ vaccine were better protected than either unvaccinated children or those given the Schwarz vaccine.
Original languageEnglish
JournalLancet
Volume2
Issue number8615
Pages (from-to)809-11
Number of pages3
ISSN0140-6736
Publication statusPublished - 1988

    Fingerprint

Keywords

  • Age Factors
  • Clinical Trials as Topic
  • Drug Evaluation
  • Female
  • Guinea-Bissau
  • Humans
  • Immunization Schedule
  • Infant
  • Measles
  • Measles Vaccine
  • Random Allocation
  • Urban Population
  • Vaccination

Cite this

Aaby, P., Jensen, T. G., Hansen, H. L., Kristiansen, H., Thårup, J., Poulsen, A., Sodemann, M., Jakobsen, M., Knudsen, K., & Clotilde da Silva, M. (1988). Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet, 2(8615), 809-11.